Loading
A phase 1/2 trial of pembrolizumab in pancreatic cancer, run by Essen Biotech, now recruiting.
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors is a phase 1/2, interventional study registered as NCT07410676 by Essen Biotech, with a registry enrolment figure of 83 participants, started 2026-02-01 and due to reach its primary completion in 2028-12-21. Interventions recorded: EBNK-001 + IL-15 + Pembrolizumab. Conditions listed: Cancer; Sarcoma; Leukaemia; Breast Cancer (Locally Advanced or Metastatic); Lung Cancer (Diagnosis); Colorectal Cancer; Melanoma (Skin Cancer); Bladder Cancer; Kidney Cancer; Pancreatic Cancer Metastatic; Liver Cancer (Primary and Metastatic); Ovarian Cancer; Esophageal Cancer; Glioblastoma; Non-Melanoma Skin Cancer. Primary outcome: Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs); Incidence of Dose-Limiting Toxicities (DLTs). Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Pembrolizumab, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/